Galixir

Galixir is an artificial intelligence technology to promote the research and development of new drugs. Our artificial intelligence drug discovery platform can help drug research and development scientists greatly save time and cost in drug development. At the same time, our platform also provides comprehensive patent protection coverage for the drugs developed. Relying on cutting-edge artificial intelligence technology, Xingyao combines engineering chemistry, computational chemistry, computational biology, and cloud computing technologies to serve the various processes of drug development.

Galixir headquartered in Asia, operates in the Cloud Computing, Biotechnology, Artificial Intelligence (AI), Product Research sector. The company focuses on Cloud Computing and has secured $320.0M in funding across 32 round(s). With a team of 101-250 employees, Galixir is actively contributing to advancements in Cloud Computing. Their latest funding round, Series A - Galixir, raised $Unknown amount. Discover more about their projects, partnerships, and impact on our platform.